Ten-year Clinical Outcomes in >1000 Node-negative (N0) Estrogen Receptor (ER)+ Breast Cancer (BC) Patients (Pts) in Whom Treatment Decisions Incorporated the Recurrence Score Results: A Registry Analysis Using TAILORx Categorization

Poster Abstracts

SM Stemmer1, 2, M Steiner3, S Rizel1, N Ben-Baruch4, B Uziely5, DM Jakubowski6, J Baron6, S Shak6, L Soussan-Gutman7, A Bareket-Samish8, G Fried9, O Rosengarten10, A Itay11, B Nisenbaum12, D Katz13, M Leviov3, M Tokar14,15, DB Geffen14,15, N Liebermann16

1Rabin Medical Center, Petah Tikva, Israel
2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3Lin Medical Center, Haifa, Israel
4Kaplan Medical Center, Rehovot, Israel
5Hadassah-Hebrew University Medical Center, Jerusalem, Israel
6Genomic Health Inc., Redwood City, CA
7Oncotest Division, Teva Pharmaceutical Industries, Ltd., Shoham, Israel
8BioInsight Ltd, Zichron Yaakov, Israel
9Rambam Health Care Campus, Haifa, Israel
10Shaare Zedek Medical Center, Jerusalem, Israel
11Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
12Meir Medical Center, Kfar Saba, Israel
13Assaf Harofeh Medical Center, Zerifin, Israel
14Soroka University Medical Center, Beer Sheva, Israel
15Faculty of Health Sciences, Ben-Gurion University of Negev, Beer Sheva, Israel
16Community Division, Clalit Health Services, Tel Aviv, Israel

Goals: To investigate 10-y clinical outcomes in N0 ER+ BC pts in whom the 21-gene Oncotype DX Breast Recurrence Score® results guided adjuvant treatment decisions in real-life clinical practice.

Methods: This exploratory analysis of the prospectively-designed Clalit Health Services (CHS) registry included all CHS pts with N0 ER+ HER2-negative BC who underwent RS testing in Israel between 1/2006 and 12/2009. Ten-year Kaplan-Meier estimates for distant recurrence and BC-specific mortality (BCSM) rates are reported.

Results: The analysis included 1365 pts (median follow-up: 9.0 y); 99.3% females; median age, 60 y; 50.3% grade 2 tumors, 77.1% tumors ≥2 cm. The distribution of Recurrence Score® (RS) results was as follows: RS 0-10, 17.8%; RS 11-25, 62.5%; and RS 26-100, 19.7%, with corresponding chemotherapy (CT) use of 0%, 9.4%, and 69.9%. Ten-year distant recurrence rates in RS 0-10, 11-25, and 26-100 pts: 2.6% (95% confidence interval [CI], 1.1%, 6.2%), 6.1% (95% CI, 4.4%, 8.6%), and 13.1% (95% CI, 9.4%, 18.3%), respectively (P<.001). The corresponding BCSM rates: 0.7% (95% CI, 0.1%, 5.1%), 2.2% (95% CI, 1.3%, 3.7%), and 9.5% (95% CI, 6.0%, 14.9%) (P<.001). Subdividing the RS 11-25 group revealed 10-year distant
recurrence rates of 4.0% (95% CI, 2.0%, 7.7%), 5.8% (95% CI, 3.2%, 10.3%), and 8.9% (95% CI, 5.4%, 14.5%) in the RS 11-15, 16-20, and 21-25 subgroups, respectively (corresponding CT use in these 3 subgroups, 1.8%, 7.0%, and 21.6%). When the analysis included pts treated with endocrine therapy alone (95.5%/87.5% of pts with RS 0-10/11-25), 10-y distant recurrence and BCSM rates for RS 0-10 pts were 2.7% (95% CI, 1.1%, 6.5%) and 0.8% (95% CI, 0.1%, 5.3%), respectively, and for pts with RS 11-25, 5.7% (95% CI, 3.9%, 8.3%) and 6.9% (95% CI, 2.6%, 17.8%), respectively. No statistically significant differences were observed in 10-year distant recurrence/BCSM rates in CT-treated vs untreated pts in the RS 11-25 subgroup; however, this should be interpreted cautiously since the number of events was low and pts were not randomized. Notably, of 243 pts with RS 0-10, none received CT. Of the 853 pts with RS 11-25, 9/273, 13/344, and 16/236 distant recurrence events were observed in the RS 11-15, RS 16-20, and RS 21-25 groups, respectively.

**Conclusions:** In NO ER+ HER2-negative BC pts, in whom the decision to use CT was closely aligned with RS results, those with RS 0-25 (~80% of patients) had excellent outcomes at ten years, despite CT use in <10% of pts.